<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Preclinical models for neuroblastoma: establishing a baseline for treatment.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Preclinical models for neuroblastoma: establishing a baseline for treatment." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5b0/3084749/57b75465e420/pone.0019133.g008.jpg"/> </div> <div class="text-side"> <h1>Preclinical models for neuroblastoma: establishing a baseline for treatment.</h1> <p>Morphology and immunohistochemistry of regressing TH-MYCN
tumors.(A), Regressing tumor 620 stained with H&amp;E, B-cell
marker, B220 (B), T-Cell marker, CD3 (C),
macrophage cells marker F4-80 (D), a CD8 T-cells and
natural killer cells marker Perforin-1 (E) and cleaved
caspase-3 (F). Regressing tumor 6865 stained with cleaved
caspase-3 (G, H).</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21559450/" target="_blank">21559450</a></p><p>Type: Premalignant/Malignant, Category: Neural or neuroendocrine</p>
</div> </div></div></body></html>